> Chemicals & Drugs > Amino Acid > Carcinoembryonic Antigen

Carcinoembryonic Antigen

Carcinoembryonic Antigen (CEA): A glycoprotein tumor marker expressed in various types of cancers, including colorectal, breast, and lung carcinomas.
CEA plays a role in cell adhesion and can be used for cancer screening, diagnosis, and monitoring treatment response.
PubCompare.ai's AI-powered platform helps researchers optimize CEA-related research protocols, improve reproducibility, and streamline their workflow.
Discover the best protocols and products from literature, pre-prints, and patents through AI-driven comparisons to enhance the reliability of your CEA findings.

Most cited protocols related to «Carcinoembryonic Antigen»

Multicenter Randomized Rectal Cancer Trial

Cited 8 times

This was a multicenter balanced randomized trial conducted in the United States and Canada (Figure) (protocol in Supplement 1). Eligible patients were aged 18 years or older, had a body mass index of 34 or less, had an Eastern Cooperative Oncology Group performance score less than 3, and had histologically proven adenocarcinoma of the rectum at or below 12 cm above the anal verge (by rigid proctoscopy), with clinical stage II, IIIA, IIIB (T3N0M0, TanyN1 or 2, M0, and no T4) determined by rectal cancer protocol magnetic resonance imaging or transrectal ultrasonography. Clinical staging (including carcinoembryonic antigen levels, liver function tests, and computed tomography of chest, abdomen, and pelvis) was performed before neoadjuvant therapy. Race/ ethnicity was self-reported by patients in accordance with fixed categories and collected to determine generalizability of the conclusions. All patients were to have completed fluorouracil-based chemoradiotherapy or radiotherapy alone, according to institution-specific protocols (registered with the study), and the operation was to have been performed within 4 to 12 weeks of the final radiation treatment. Exclusion criteria were as follows: a history of invasive pelvic malignancy within 5 years, psychiatric or addictive disorders that affected compliance to the protocol, severe incapacitating disease (American Society of Anesthesiologists classification IV or V), systemic disease that would preclude use of a laparoscopic approach (eg, cardiovascular, renal, hepatic), or conditions that would limit the success of laparoscopic resection (multiple previous laparotomies or severe adhesions).
Surgeons were credentialed before patient enrollment (requirements in Appendix B in Supplement 2). The study protocol was approved by the individual participating institutions’ review boards, as well as the central institutional review board for the National Cancer Institute. All participants gave written informed consent before study enrollment.

Fleshman J., Branda M., Sargent D.J., Boller A.M., George V., Abbas M., Peters WR J.r., Maun D., Chang G., Herline A., Fichera A., Mutch M., Wexner S., Whiteford M., Marks J., Birnbaum E., Margolin D., Larson D., Marcello P., Posner M., Read T., Monson J., Wren S.M., Pisters P.W, & Nelson H. (2015). Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial. JAMA, 314(13), 1346-1355.

Publication 2015

Abdomen Addictive Behavior Adenocarcinoma Anesthesiologist Anus Carcinoembryonic Antigen Cardiovascular System Chemoradiotherapy Chest Dietary Supplements Ethics Committees, Research Ethnicity Fluorouracil Index, Body Mass Kidney Laparoscopy Laparotomy Liver Function Tests Muscle Rigidity Neoadjuvant Therapy Neoplasms Patients Pelvic Cancer Pelvis Proctoscopy Protocol Compliance Radiotherapy Rectal Cancer Rectum Surgeons Tissue Adhesions Ultrasonography X-Ray Computed Tomography

Colonoscopy Symptom Prediction Protocol

Cited 6 times

The Colonoscopy Research Into Symptom Prediction questionnaire was used to record symptoms and demographic data. This had been translated into Spanish after receiving permission from the authors [20 (link)]. Nurses specifically trained in the assessment of gastrointestinal symptoms administered the questionnaire to the patients. They also collected administrative information and determined if patients met any of the NICE referral criteria for CRC detection: patients ≥40 years with rectal bleeding and a change of bowel habit persisting ≥6 weeks; patients ≥60 years with rectal bleeding persisting ≥6 weeks without a change in bowel habit and without anal symptoms; patients ≥60 years with a change in bowel habit persisting ≥6 weeks without rectal bleeding; patients presenting a right lower abdominal mass consistent with involvement of the large bowel; patients presenting with a palpable rectal mass; or patients with unexplained iron deficiency anaemia (<11 g/100 mL in men, <10 g/100 mL in non–menstruating women) [3 ].
All individuals collected a faeces sample from one bowel movement without specific diet or medication restrictions the week before the colonoscopy. They were specifically instructed to sample a stool where no blood was visible. f-Hb concentration was assessed using the automated OC-SENSOR™ (Eiken Chemical Co., Tokyo, Japan) and faecal calprotectin was determined using a commercial ELISA kit (Bühlmann fCAL ELISA calprotectin, Bühlmann Laboratories AG, Basel, Switzerland). The stool sample for the f-Hb determination was collected using the OC-SENSOR probe. The stool sample for the faecal calprotectin determination was collected independently. We determined blood haemoglobin (b-Hb) and mean corpuscular volume with a Beckman Coulter Autoanalyzer (Beckman Coulter Inc., CA, USA) and serum carcinoembryonic antigen (CEA) using a chemiluminescent microparticle immunoassay (UniCel DXI 800; Beckman Coulter).

Cubiella J., Vega P., Salve M., Díaz-Ondina M., Alves M.T., Quintero E., Álvarez-Sánchez V., Fernández-Bañares F., Boadas J., Campo R., Bujanda L., Clofent J., Ferrandez Á., Torrealba L., Piñol V., Rodríguez-Alcalde D., Hernández V, & Fernández-Seara J. (2016). Development and external validation of a faecal immunochemical test-based prediction model for colorectal cancer detection in symptomatic patients. BMC Medicine, 14(1), 128.

Full text: Click here

Publication 2016

Abdomen Anus BLOOD Carcinoembryonic Antigen Cell-Derived Microparticles Colonoscopy Defecation Diet Enzyme-Linked Immunosorbent Assay Erythrocyte Volume, Mean Cell Feces Hemoglobin Hispanic or Latino Immunoassay Iron Deficiency Anemia Large Intestine Leukocyte L1 Antigen Complex Nurses Patients Pharmaceutical Preparations Rectum Serum Woman

Quantifying Chemokine and CEA Expression

Cited 5 times

The commercially available TaqMan Gene Expression Assays Hs01650998_m1, Hs00171042_m1, Hs00171065_m1, Hs00234140_m1, Hs01567026_m1 and Hs00154355_m1 (Applied Biosystems, Foster City, CA, USA) in combination with TaqMan EZ technology (Applied Biosystems) were used to determine the expression levels of CXCL17, CXCL10, CXCL9, CCL2, CD86 and CD68, respectively. The RT–PCR profile was 50 °C for 2 min, 60 °C for 30 min and 95 °C for 5 min followed by 45 cycles of 95 °C for 20 s and 60 °C for 1 min. Emission from the released reporter dye was measured by the ABI Prism 7700 Sequence Detection System (Applied Biosystems). All qRT–PCR analyses were carried out in triplicates. The concentration of 18S rRNA was determined in each sample by real-time qRT–PCR (Applied Biosystems) for normalisation of chemokine mRNA levels (Bas et al, 2004 (link)). Chemokine expression levels in primary tumours and cell lines are expressed as relative quantity (RQ) calculated according to the equation: 2^-(Δct of the sample−the median Δct value of the normal colon tissue samples). Δct is the ct value of the chemokine mRNA minus the ct value of 18S rRNA in the same sample. Concentrations of mRNA for carcinoembryonic antigen (CEA) were determined by using a qRT–PCR constructed in the laboratory using the TaqMan EZ technology (Applied Biosystems) and an external RNA copy standard (Öberg et al, 2004 (link)). CEA mRNA levels were estimated by dividing the CEA mRNA concentration with the concentration of 18S rRNA in the same sample, as determined by qRT–PCR for 18S rRNA (Applied Biosystems) and an external standard of total RNA from polyclonally activated human PBMCs. An amount of 1 pg RNA is defined as one unit (U) of 18S rRNA that corresponds approximately to 1 epithelial cell (Fahlgren et al, 2003 (link)).

Ohlsson L., Hammarström M.L., Lindmark G., Hammarström S, & Sitohy B. (2016). Ectopic expression of the chemokine CXCL17 in colon cancer cells. British Journal of Cancer, 114(6), 697-703.

Publication 2016

Biological Assay Carcinoembryonic Antigen CCL2 protein, human Cell Lines Chemokine Colon CXCL9 protein, human Epithelial Cells Gene Expression Homo sapiens Neoplasms pgRNA prisma Real-Time Polymerase Chain Reaction Reverse Transcriptase Polymerase Chain Reaction RNA, Messenger RNA, Ribosomal, 18S Tissues

Colorectal Cancer Surveillance Protocol

Cited 5 times

Since 1982, all patients undergoing surgery for colorectal cancer at the Department of Surgery, Klinikum rechts der Isar, Technische Universität München, Munich, Germany, are scheduled for periodic follow-up at our interdisciplinary ambulatory tumor center or outside of our hospital according to the recommendations of the German Cancer Society. The recommendations include—over a period of at least 5 years—regular physical examination, blood analysis, determination of carcinoembryonic antigen level, abdomen ultrasonography/computed tomography, chest radiography, and colonoscopy. All patient data are prospectively entered in a database, including preoperative tumor staging, preoperative multimodal treatment, details of the surgical procedure, occurrence of complications, postoperative histopathology, application of adjuvant or palliative treatment, and follow-up (date of last visit, date and site of tumor recurrence, date of tumor-related or unrelated death, cause-specific and recurrence-free survival).15 (link) Information from patients followed outside of our institution is obtained by periodic phone calls to the responsible general practitioners or gastroenterologists.
For this analysis, consecutive complete data sets of patients with resection of colorectal AC, MAC, or SC were extracted. Patients with other histological subtypes and patients without oncological resection of their primary tumor were not included. The latest date of inclusion and follow-up was October 1, 2012. Histological, clinical, and survival data of patients with classical AC were compared with those of patients with MAC and SC. All patients were staged according to the seventh edition of the International Union Against Cancer (UICC)/American Joint Committee on Cancer (AJCC) tumor staging system.

Nitsche U., Zimmermann A., Späth C., Müller T., Maak M., Schuster T., Slotta-Huspenina J., Käser S.A., Michalski C.W., Janssen K.P., Friess H., Rosenberg R, & Bader F.G. (2013). Mucinous and Signet-Ring Cell Colorectal Cancers Differ from Classical Adenocarcinomas in Tumor Biology and Prognosis. Annals of Surgery, 258(5), 775-783.

Publication 2013

Abdomen Carcinoembryonic Antigen Colonoscopy Colorectal Carcinoma Combined Modality Therapy Gastroenterologist General Practitioners Hematologic Tests Joints Malignant Neoplasms Neoplasms Operative Surgical Procedures Palliative Care Patients Pharmaceutical Adjuvants Physical Examination Radiography, Thoracic Recurrence Ultrasonography X-Ray Computed Tomography

Epithelioid Malignant Pleural Mesothelioma Study

Cited 5 times

Clinical and pathological information on 232 patients diagnosed with epithelioid diffuse malignant pleural mesothelioma between 1989 and 2009 at Memorial Sloan-Kettering Cancer Center was collected through the Thoracic Surgery mesothelioma database and the Department of Pathology data file. Institutional Review Board approval was obtained for this study. Clinical variables recorded in the prospectively maintained database included age, gender, laterality, TNM stage, and surgical procedure. TNM staging was based on the reported imaging findings, the surgeon’s intraoperative findings, and the pathologic evaluation of the resected specimens using the sixth edition of the American Joint Commission on Cancer Staging Manual.¹⁸ All patients were followed until date of death or last follow-up.
Pathologic diagnosis was based on standard histologic, histochemical, and immunohistochemical criteria.^{1 ,19 (link),20} As a positive marker of immunohistochemistry for malignant pleural mesothelioma, standard immunohistochemical markers included calretinin, WT-1, cytokeratin 5/6, and D2-40. As negative markers for malignant pleural mesothelioma, we used carcinoembryonic antigen, CD15, B72.3, BerEP4, and thyroid transcription factor-1. In cases before positive mesothelial markers were available, negative markers were used for making the diagnosis of malignant pleural mesothelioma. In order to confirm original diagnosis, for specimens where tumor blocks were available, we performed immunohistochemistry for calretinin and WT-1. Only one case was negative for both markers; however, this particular patient’s clinical and radiological findings were characteristic of diffuse malignant pleural mesothelioma. The pathological diagnosis was correlated with the gross distribution of tumor and the absence of an intrapulmonary mass lesion on radiologic imaging.

Kadota K., Suzuki K., Colovos C., Sima C.S., Rusch V.W., Travis W.D, & Adusumilli P.S. (2011). A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 25(2), 260-271.

Publication 2011

B72.3 antibody Calretinin Carcinoembryonic Antigen Diagnosis Ethics Committees, Research Functional Laterality Gender Immunohistochemistry Joints Keratin-6 Malignant Neoplasms Malignant Pleural Mesothelioma Mesothelioma Mesothelium Neoplasms NKX2-1 protein, human Operative Surgical Procedures Patients Surgeons Thoracic Surgical Procedures X-Rays, Diagnostic

Most recents protocols related to «Carcinoembryonic Antigen»

Simultaneous CD40 and CEACAM5 Targeting

Not available on PMC !

Example 4

Aim

The aim of the study was to evaluate the ability of selected CD40 and CEACAM5 targeting RUBY™ bsAbs to bind both their targets simultaneously as well as their potential cross-reactivity with additional members of the CEA protein family was evaluated by ELISA.

Materials and Methods

96-well plates were coated with 0.5 μg/mL antigen, hCEACAM-1 (2244-CM-050, R&D Systems), hCEACAM-5 (4128-CM-050, R&D Systems), hCEACAM-6 (3934-CM-050, R&D Systems) or CEACAM-8 (9639-CM-050, R&D Systems) in PBS over night at 4° C. After washing in PBS/0.05% Tween 20 (PBST), the plates were blocked with PBST, 2% BSA for at least 30 minutes at room temperature before a second round of washing. RUBY bsAbs, diluted in PBST, 0.5% BSA, were then added and allowed to bind for at least 1 hour at room temperature. After washing, plates were incubated with either 50 μl detection antibody (0.5 μg/ml HRP conjugated goat anti human-kappa light chain, #STAR127P, AbD Serotec) for analysis of binding to CEACAM protein family proteins or 0.5 μg/ml biotinylated hCD40-muIg (504-030, Ancell) followed by HRP conjugated streptavidin (21126, Pierce) for confirmation of dual antigen binding. Finally, a final round of washing was performed and bound complexes detected using SuperSignal Pico Luminescent as substrate and luminescence signals were measured using Fluostar Optima.

Results and Conclusions

All evaluated RUBY™ bsAbs was indeed able to bind to both CD40 and human CEACAM5 simultaneously (FIG. 2), although with varying potency. In general, bsAbs carrying 1132 as CD40 binding antibody (Multi46-Multi49) displayed lower potency in the dual target ELISA, as compared to bsAbs carrying G12_mut. Also, Multi38 displayed reduced dual target binding compared to other G12_mut based bsAbs, likely due to lower CEACAM5 binding of Fab6 than other evaluated CEACAM5 binding antibodies.

As can be seen in FIG. 3, a majority of the evaluated CD40 and CEACAM5 targeting RUBY™ bsAbs did not cross react with any of the other CEA family members evaluated. However, a limited number of the assayed bsAb did show significant cross-reactivity with CEACAM1 (Multi38, Multi39, Multi45 and Multi 49) or CEACAM6 (Multi40).

All in all, it can be concluded that all evaluated RUBY™ bsAbs have the ability to bind CD40 and CEACAM5 simultaneously and a majority of the set was specific for CEACAM5, with no or little detectable binding to other evaluated members of the CEA protein family.

US11873348B2. Peptides (2024-01-16). ALLIGATOR BIOSCIENCE AB [SE]. Inventors: Peter Ellmark [SE], Karin Hagerbrand [SE], Laura Varas [SE], Mattias Levin [SE], Anna Säll [SE], Laura von Schantz [SE].

Full text: Click here

Patent 2024

Antibodies Antigens biliary glycoprotein I Binding Proteins Carcinoembryonic Antigen carcinoembryonic antigen-related cell adhesion molecule 6, human Cross Reactions Enzyme-Linked Immunosorbent Assay Family Member Gene Products, Protein Goat Homo sapiens Immunoglobulin kappa-Chains Immunoglobulins Luminescence Streptavidin Tween 20 Vision

Comprehensive Profiling of Intrahepatic Cholangiocarcinoma

This study included five ICC patient cohorts. (1) The FU-iCCA cohort enrolled 262 ICC patients from Zhongshan Hospital, Fudan University [22 (link)]. Multi-omics data of this cohort, including data of whole-exome sequencing (WES), RNA sequencing, and proteome, were analyzed. (2) The second cohort recruited 259 patients with pathologically confirmed ICC undergoing curative resection in Zhongshan Hospital (ZSH cohort) from June 2012 to December 2017. All enrolled patients received no anti-cancer therapy prior to surgery. All tumor specimens from the ZSH cohort were formalin-fixed and paraffin-embedded and collected for tissue microarrays (TMA) construction. The ZSH cohort was used to validate the findings from the FU-iCCA cohort. The baseline characteristics of the FU-iCCA cohort and the ZSH cohort are detailed in Table 1. Serological tests were performed within 3 days before the operation. The clinical stage was evaluated based on the American Joint Committee on Cancer (AJCC) 8th edition [23 (link)]. (3) The third cohort included five ICC patients from the single-cell RNA sequencing dataset GSE138709 [24 (link)]. (4) We extracted the single-cell data of ten ICC patients for the immune checkpoint blockade (ICB) clinical trial (ICB cohort) from GSE151530 and divided them into two groups (baseline group and ICB-treated group) [25 (link)]. (5) The fifth cohort recruited an independent cohort of 33 ICC patients receiving surgical resection from January 2019 to June 2019 in Zhongshan Hospital. CD73 expression between matched tumor and para-tumor tissues was compared by RT-PCR assays.Table 1

Correlation between CD73 expression and clinical features of patients enrolled

Characteristics	FU-iCCA cohort (n = 244)					ZSH cohort (n = 259)
	Patients		CD73 expression			Patients		CD73 expression
	No	%	Low	High	P value	No	%	Low	High	P value
All patients	244	100	140	104		259	100	146	113
Sex
Female	106	43.4	62	44	0.758	99	38.2	67	32	0.004
Male	138	56.6	78	60		160	61.8	79	81
Age
≤ 60	113	46.3	67	46	0.574	125	48.3	69	56	0.714
> 60	131	53.7	73	58		134	51.7	77	57
HBsAg
Negative	179	73.4	104	75	0.705	179	69.1	97	82	0.290
Positive	65	26.6	36	29		80	30.9	49	31
Liver cirrhosis
No	222	91.0	128	94	0.778	186	71.8	104	82	0.813
Yes	22	9.0	12	10		73	28.2	42	31
Vascular invasion
No	141	57.8	87	54	0.110	185	71.4	115	70	0.003
Yes	103	42.2	53	50		74	28.6	31	43
LN metastasis
No	194	79.5	114	80	0.389	207	79.9	124	83	0.022
Yes	50	20.5	26	24		52	20.1	22	30
Tumor size
≤ 5 cm	108	44.3	63	45	0.788	116	44.8	71	45	0.158
> 5 cm	136	55.7	77	59		143	55.2	75	68
CA199
≤ 37 U/mL	109	44.7	75	34	0.001	116	44.8	76	40	0.008
> 37 U/mL	135	55.3	65	70		143	55.2	70	73
CEA
≤ 5 ng/mL	185	75.8	116	69	0.003	189	73.0	118	71	0.001
> 5 ng/mL	59	24.2	24	35		70	27.0	28	42
AJCC 8th
I–II	154	63.1	96	58	0.040	203	78.4	122	81	0.021
III–IV	90	36.9	44	46		56	21.6	24	32

Data in bold indicated statistical significance

ZSH cohort Zhongshan Hospital cohort, LN Lymph node, CEA Carcinoembryonic antigen, AJCC American Joint Committee on Cancer

Sun B.Y., Yang Z.F., Wang Z.T., Liu G., Zhou C., Zhou J., Fan J., Gan W., Yi Y, & Qiu S.J. (2023). Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma. World Journal of Surgical Oncology, 21, 90.

Full text: Click here

Publication 2023

Biological Assay Carcinoembryonic Antigen Formalin Immune Checkpoint Blockade Inpatient Joints Liver Cirrhosis Malignant Neoplasms Microarray Analysis Neoplasm Metastasis Neoplasms Nodes, Lymph NT5E protein, human Operative Surgical Procedures Paraffin Patients Proteome Reverse Transcriptase Polymerase Chain Reaction Tests, Serologic Therapeutics Tissues

Hematological Biomarkers in Diagnostic Evaluation

Baseline and clinical characteristics, as well as laboratory measurements of each eligible individual, were obtained from the electronic medical record system of the Affiliated Hospital of Jiangsu University. The latest peripheral blood samples were collected from patients with an empty stomach in the early morning before diagnosis and any treatment, with a time span of no more than 1 week between the two. Routine blood tests were performed using a SYSMEX XN3000 automated haematology analyzer (Sysmex Corporation). Serum albumin was detected using a BEKMAN AU5800 automatic biochemical analyzer (Beckman Coulter, Inc.). The serum carcinoembryonic antigen (CEA) and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) levels were determined using the ABBOTT ARCHITECT i2000sr (Abbott Pharmaceutical Co., Ltd.) and MAGLUMI X8 Analyzer (Shenzhen New Industry Biological Engineering Co., Ltd.), respectively, using a chemiluminescence immunoassay with kits from the corresponding manufacturer (cat. no. 7K68-78; cat. no. 130201013M). The normal range of all indicators was recorded according to the manufacturer's instructions. The MRR, NRR, LRR and LA of each group were calculated as follows: MRR was defined as the monocyte count (×10⁹/l) to red blood cell count (×10¹²/l) ratio, NRR was defined as the neutrophil count (×10⁹/l) to red blood cell count (×10¹²/l) ratio, LRR was defined as the lymphocyte count (×10⁹/l) to red blood cell count (×10¹²/l) ratio, and LA was defined as the product of the lymphocyte count (×10⁹/l) and albumin concentration (g/l).

Chen X.X., Zhao S.T., Yang X.M., He S.C, & Qian F.H. (2023). Additional diagnostic value of the monocyte to red blood cell count ratio and the product of lymphocyte count and albumin concentration in lung cancer management. Oncology Letters, 25(4), 135.

Publication 2023

Albumins antigen CYFRA21.1 Antigens BLOOD Carcinoembryonic Antigen Chemiluminescent Assays Diagnosis Erythrocyte Count Hematologic Tests Lymphocyte Count Monocytes Neutrophil Patients Pharmaceutical Preparations Serum Serum Albumin Stomach

Comprehensive Clinical Biomarker Profiling

Demographic variables collected for the study included age, sex, smoking status, and medical history. Basic clinical variables included tumor stage, site, size, pathological type, and genotype (Table 1). A total of 46 laboratory test index variables were included in the study, including: white blood cell count (WBC), red blood cell count (RBC), platelet (PLT), hemoglobin (Hb), neutrophil count (NEUT), lymphocyte count (LYM), monocyte count (MONO), eosinophil count (EOS), basophil count (BASO), prothrombin time (PT), activate part plasma prothrombin time (APTT), fibrinogen (FIB), D-dimer, international normalized ratio (INR), arterial oxygen partial pressure (PaO), arterial blood carbon dioxide partial pressure (PaCO₂), arterial oxygen saturation (SaO), pH, base excess (BE), standard bicarbonate (SB), uric acid (UA), α-hydroxybutyrate dehydrogenase (α-HBDH), total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL), creatinine (Cr), blood urea nitrogen (BUN), blood sugar (GLU), serum potassium ion (K), sodium ion (Na), serum chlorine (CL), serum calcium (Ca), carbon dioxide combining power (CO₂CP), aspartate aminotransferase (AST), serum creatine kinase (CK), serum creatine kinase isoenzyme (CK-MB), lactate dehydrogenase (LDH), alpha-L-fucosidase (AFU), carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), neuron specific enolase (NSE), carbohydrate antigen 125 (CA125), carbohydrate antigen 153 (CA153), and systolic and diastolic blood pressure.

Ou L., Cai X., Zeng W., Huang L., Deng Q., Tang H., Chen Z., Zhou H., Lin Y., Liu L, & Liang W. (2023). Laboratory blood test profiling reveals distinct biochemical and hemocyte features of KRAS mutated non-small cell lung cancer. Journal of Thoracic Disease, 15(2), 365-375.

Publication 2023

Activated Partial Thromboplastin Time alpha-hydroxybutyrate dehydrogenase antigen CYFRA21.1 Antigens Arteries Basophils Bicarbonates BLOOD Blood Glucose Blood Platelets CA-125 Antigen Calcium, Dietary Carbohydrates Carbon dioxide Carcinoembryonic Antigen Chlorine Cholesterol Cholesterol, beta-Lipoprotein Creatine Kinase Creatinine Eosinophil Erythrocyte Count fibrin fragment D Fibrinogen Fucosidase gamma-Enolase Genotype Hemoglobin High Density Lipoprotein Cholesterol International Normalized Ratio Isoenzyme CPK MB Isoenzymes Lactate Dehydrogenase Leukocyte Count Lymphocyte Count Monocytes Neoplasms Neutralization Tests Neutrophil Oxygen Oxygen Saturation Partial Pressure Plasma Potassium Pressure, Diastolic Serum Sodium Systole Times, Prothrombin Transaminase, Serum Glutamic-Oxaloacetic Triglycerides Urea Nitrogen, Blood Uric Acid

Multivariable Model for HER2+ AGC Prognosis

The objective was to develop and externally validate a multivariable model to stratify patients with HER2+ AGA according to PFS/OS. Outcome variables were PFS and OS defined as the time in months between initiation of first-line chemotherapy and progression or death, respectively, censoring subjects alive at last follow-up.
Candidate predictors were selected after an exhaustive literature search, and after consultation with experts from the participating centres. No data-driven method was used in the final selection of variables.²¹ All covariates had to be available at the start of treatment (e.g. the primary tumour surgery variable was only considered when subjects had been exposed before the start of first-line treatment). The covariates considered in this model were age, Eastern Cooperative Oncology Group performance status (ECOG PS; ⩾2 versus 0–1), primary tumour location (oesophagus, GEJ, stomach), HER2 expression level (IHC 2+/FISH+ versus IHC 3+), Lauren subtype (intestinal versus diffuse and mixed), signet ring cells, histological grade (1, 2, versus 3), overall tumour burden (stratified into four categories, Table 1), neutrophil-to-lymphocyte ratio (NLR; non-linear, continuous), albumin, carcinoembryonic antigen, CEA (non-linear, continuous), primary tumour surgery, chemotherapy regimen (anthracycline-based triplets, carboplatin–5-fluorouracil, carboplatin–capecitabine, cisplatin–5-fluorouracil, docetaxel-containing regimens, 5-fluorouracil/oxaliplatin, capecitabine/oxaliplatin, capecitabine/cisplatin, others). Criteria to stratify the overall tumour burden (Table 1) have been used previously by our group.²² The OS analyses stratified by this variable on the entire cohort, as well as the Manchester series, suggest that these criteria are valid (Supplemental Annex Figure 1).

Jimenez-Fonseca P., Foy V., Raby S., Carmona-Bayonas A., Macía-Rivas L., Arrazubi V., Cacho Lavin D., Hernandez San Gil R., Custodio A., Cano J.M., Fernández Montes A., Mirallas O., Macias Declara I., Vidal Tocino R., Visa L., Limón M.L., Pimentel P., Martínez Lago N., Sauri T., Martín Richard M., Mangas M., Gil Raga M., Calvo A., Reguera P., Granja M., Martín Carnicero A., Hernández Pérez C., Cerdá P., Gomez Gonzalez L., Garcia Navalon F., Pacheco Barcia V., Gutierrez Abad D., Ruiz Martín M., Weaver J., Mansoor W, & Gallego J. (2023). The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy. Therapeutic Advances in Medical Oncology, 15, 17588359231157641.

Publication 2023

Albumins Anthracyclines Capecitabine Carboplatin Carcinoembryonic Antigen Cells Cisplatin Disease Progression Docetaxel Electrocorticography ERBB2 protein, human Esophagus Fishes Fluorouracil Intestines Lymphocyte Neoplasms Neoplasms by Site Neutrophil Operative Surgical Procedures Oxaliplatin Patients Pharmacotherapy Stomach Treatment Protocols Triplets Tumor Burden XELOX

Top products related to «Carcinoembryonic Antigen»

Cobas e601 by Roche

Sourced in Germany, Switzerland, United States, China, Sweden, United Kingdom, Japan, Canada

The Cobas e601 is an automated immunochemistry analyzer used for in vitro diagnostic testing. It is designed to perform a wide range of immunoassay tests, including those for hormones, tumor markers, and infectious diseases. The Cobas e601 utilizes electrochemiluminescence technology to provide accurate and reliable results.

Bovine serum albumin (bsa) by Merck Group

Sourced in United States, Germany, United Kingdom, China, Italy, Japan, France, Sao Tome and Principe, Canada, Macao, Spain, Switzerland, Australia, India, Israel, Belgium, Poland, Sweden, Denmark, Ireland, Hungary, Netherlands, Czechia, Brazil, Austria, Singapore, Portugal, Panama, Chile, Senegal, Morocco, Slovenia, New Zealand, Finland, Thailand, Uruguay, Argentina, Saudi Arabia, Romania, Greece, Mexico

Bovine serum albumin (BSA) is a common laboratory reagent derived from bovine blood plasma. It is a protein that serves as a stabilizer and blocking agent in various biochemical and immunological applications. BSA is widely used to maintain the activity and solubility of enzymes, proteins, and other biomolecules in experimental settings.

Xe 2100 by Sysmex

Sourced in Japan, Germany, United Kingdom, United States, Brazil

The XE-2100 is a hematology analyzer designed for automated blood cell analysis. It provides comprehensive analysis of various blood cell types, including red blood cells, white blood cells, and platelets. The XE-2100 is capable of performing a wide range of hematological tests and measurements to support clinical decision-making.

Cobas 8000 by Roche

Sourced in Switzerland, Germany, United States, Japan, France, Italy, China, United Kingdom, Sweden

The Cobas 8000 is a modular, automated in-vitro diagnostic system designed for high-throughput clinical chemistry and immunochemistry testing. It is used to perform a wide range of laboratory tests, including those for chemistry, immunoassay, and electrolyte analysis. The Cobas 8000 is capable of processing a large volume of samples efficiently and accurately.

Fetal bovine serum (fbs) by Thermo Fisher Scientific

Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal

Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.

Au5800 by Beckman Coulter

Sourced in United States, Japan, Germany, United Kingdom, China, Italy, Canada

The AU5800 is a chemistry analyzer designed for high-throughput clinical laboratory testing. It features advanced optics and automation to provide reliable and efficient sample processing. The core function of the AU5800 is to perform a variety of clinical chemistry tests, including immunoassays, on patient samples.

Cobas e601 platform by Roche

Sourced in Switzerland

The Cobas e601 platform is an automated immunoassay analyzer designed for in vitro diagnostic testing. It is capable of performing a variety of immunoassay tests, including those for hormones, proteins, and infectious diseases. The Cobas e601 platform is intended for use in clinical laboratories and hospital settings.

Automated cell counter by Beckman Coulter

Sourced in United States

The Automated Cell Counter is a laboratory instrument designed to rapidly and accurately count cells in a sample. It utilizes advanced optical and electronic technologies to provide precise cell counts and viability measurements.

Cobas e601 analyzer by Roche

Sourced in Germany, United States, Switzerland, China, Belgium, United Kingdom, France

The Cobas e601 analyzer is a fully automated immunoassay system used for the analysis of clinical samples. It is designed to perform a wide range of immunoassay tests, including those for hormones, tumor markers, and infectious diseases. The Cobas e601 analyzer utilizes electrochemiluminescence technology to provide accurate and reliable results.

Prism 6 by GraphPad

Sourced in United States, United Kingdom, Canada, China, Germany, Japan, Belgium, Israel, Lao People's Democratic Republic, Italy, France, Austria, Sweden, Switzerland, Ireland, Finland

Prism 6 is a data analysis and graphing software developed by GraphPad. It provides tools for curve fitting, statistical analysis, and data visualization.

What is Carcinoembryonic Antigen (CEA) and what are its key characteristics?

Carcinoembryonic Antigen (CEA) is a glycoprotein tumor marker that is expressed in various types of cancers, including colorectal, breast, and lung carcinomas. CEA plays a role in cell adhesion and can be used for cancer screening, diagnosis, and monitoring treatment response. It is a valuable biomarker that can provide important insights into a patient's health and disease progression.

What are some common applications of CEA in healthcare and research?

CEA has several key applications in healthcare and research: - Cancer screening and early detection: CEA levels can be used to screen for certain types of cancers, allowing for earlier diagnosis and treatment. - Diagnosis and staging: CEA measurements can help diagnose the presence and stage of certain cancers. - Monitoring treatment response: Tracking CEA levels over time can indicate how well a patient is responding to cancer treatment. - Recurrence monitoring: CEA can be used to detect cancer recurrence after initial treatment.

What are some common challenges or considerations when working with CEA in research?

When working with CEA in research, there are a few key challenges and considerations to keep in mind: - CEA levels can be affected by non-cancerous conditions: Elevated CEA levels can sometimes occur in non-cancerous conditions, so it's important to interpret the results in the proper clinical context. - Variations in testing methods: There are different methods and assays used to measure CEA, which can lead to variability in results. Standardizing testing protocols is important. - Limited specificity: While CEA is a valuable biomarker, it lacks perfect specificity for cancer, so it should be used in conjunction with other diagnostic tools. - Interpreting longitudinal trends: Monitoring changes in CEA levels over time can be more informative than a single measurement.

How can PubCompare.ai help optimize CEA-related research protocols and improve reproducibility?

PubCompare.ai's AI-powered platform can be extremely helpful for optimizing CEA-related research protocols and improving reproducibility: 1. Efficently screen protocol literature: PubCompare.ai allows researchers to quickly sift through the vast body of published protocols related to CEA, saving time and effort. 2. Leverage AI to pinpoint critical insights: The platform's AI-driven analysis can highlight key differences in protocol effectiveness, enabling researchers to identify the most reliable and reproducible methods for their specific needs. 3. Enhance research reliability: By helping researchers select the best protocols and products for their CEA studies, PubCompare.ai can enhance the overall reliability and accuracy of their findings.

Are there different types or variations of Carcinoembryonic Antigen?

Yes, there are several different variations and forms of Carcinoembryonic Antigen: - CEA isoforms: CEA exists in different molecular isoforms that can have slightly different characteristics and functions. - Soluble vs. membrane-bound CEA: CEA can be found both as a soluble protein in the bloodstream as well as bound to the surface of cells. - Glycosylated vs. non-glycosylated CEA: The sugar modifications (glycosylation) of CEA can vary and impact its properties. - CEA-related cell adhesion molecules (CEACAMs): This family of proteins includes CEA as well as several related cell adhesion molecules that share structural similarities.

More about "Carcinoembryonic Antigen"

Carcinoembryonic Antigen (CEA) is a glycoprotein tumor marker that is expressed in various types of cancers, including colorectal, breast, and lung carcinomas.
CEA plays a crucial role in cell adhesion and can be utilized for cancer screening, diagnosis, and monitoring treatment response.
PubCompare.ai's AI-powered platform offers researchers the ability to optimize CEA-related research protocols, improve reproducibility, and streamline their workflow.
This innovative tool helps researchers locate the best protocols from literature, pre-prints, and patents through AI-driven comparisons, enhancing the reliability of their CEA findings.
Researchers can leverage the Cobas e601 platform, an automated immunoassay analyzer, to measure CEA levels.
The Cobas e601 utilizes Bovine Serum Albumin (BSA) as a stabilizing agent in its reagents.
Additionally, the XE-2100 and Cobas 8000 systems can be employed for automated cell counting and analysis, complementing the CEA assessment process.
The Fetal Bovine Serum (FBS) is another crucial component in cell culture experiments involving CEA, as it provides the necessary growth factors and nutrients for cell proliferation.
The AU5800 analyzer, a high-throughput clinical chemistry system, can also be utilized to support CEA-related research.
By combining the insights from PubCompare.ai's AI-powered platform with the capabilities of these analytical instruments, researchers can optimize their CEA research protocols, improve the reliability of their findings, and streamline their overall workflow for enhanced productivity and discovery.